Live feed17:15:00·271dPRReleasevia QuantisnowVertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney WeekByQuantisnow·Wall Street's wire, on your screen.VRTX· Vertex Pharmaceuticals IncorporatedHealth Care
